[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AU7132998A - Substituted pyrrolopyridines useful in the treatment of inflammatory diseases - Google Patents

Substituted pyrrolopyridines useful in the treatment of inflammatory diseases

Info

Publication number
AU7132998A
AU7132998A AU71329/98A AU7132998A AU7132998A AU 7132998 A AU7132998 A AU 7132998A AU 71329/98 A AU71329/98 A AU 71329/98A AU 7132998 A AU7132998 A AU 7132998A AU 7132998 A AU7132998 A AU 7132998A
Authority
AU
Australia
Prior art keywords
treatment
inflammatory diseases
useful
substituted pyrrolopyridines
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU71329/98A
Inventor
John H. Dodd
James R. Henry
Kenneth Rupert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ORTHO-MCNEIL Corp Inc
Original Assignee
Ortho McNeil Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho McNeil Pharmaceutical Inc filed Critical Ortho McNeil Pharmaceutical Inc
Publication of AU7132998A publication Critical patent/AU7132998A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU71329/98A 1997-04-24 1998-04-17 Substituted pyrrolopyridines useful in the treatment of inflammatory diseases Abandoned AU7132998A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4424497P 1997-04-24 1997-04-24
US60044244 1997-04-24
PCT/US1998/007831 WO1998047899A1 (en) 1997-04-24 1998-04-17 Substituted pyrrolopyridines useful in the treatment of inflammatory diseases

Publications (1)

Publication Number Publication Date
AU7132998A true AU7132998A (en) 1998-11-13

Family

ID=21931293

Family Applications (1)

Application Number Title Priority Date Filing Date
AU71329/98A Abandoned AU7132998A (en) 1997-04-24 1998-04-17 Substituted pyrrolopyridines useful in the treatment of inflammatory diseases

Country Status (4)

Country Link
AR (1) AR012593A1 (en)
AU (1) AU7132998A (en)
WO (1) WO1998047899A1 (en)
ZA (1) ZA983452B (en)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6166048A (en) 1999-04-20 2000-12-26 Targacept, Inc. Pharmaceutical compositions for inhibition of cytokine production and secretion
CN1246856A (en) 1996-11-19 2000-03-08 安姆根有限公司 Aryl and heteroaryl substituted fused pyrrole antiinflammatory agents
IL135302A0 (en) 1997-10-20 2001-05-20 Hoffmann La Roche Bicyclic kinase inhibitors
BR9814961A (en) * 1997-11-14 2000-10-03 Sankyo Co Compound or a pharmacologically acceptable salt or derivative thereof, and anti-inflammatory drugs, for the prevention or treatment of chronic rheumatism, and for the prevention or treatment of osteoarthritis
AU4694999A (en) * 1998-08-06 2000-02-28 Warner-Lambert Company Use of thiazolidinedione derivatives for the treatment or prevention of cataracts
EP1119254A4 (en) * 1998-10-07 2004-05-12 Smithkline Beecham Corp Novel treatment for stroke management
US6548503B1 (en) 1998-11-04 2003-04-15 Smithkline Beecham Corporation Pyridin-4-yl or pyrimidin-4-yl substituted pyrazines
ATE311385T1 (en) * 1999-10-27 2005-12-15 Novartis Pharma Gmbh THIAZOLE AND IMIDAZO(4,5-B)PYRIDINE COMPOUNDS AND THEIR USE AS PHARMACEUTICALS
WO2001047922A2 (en) * 1999-12-24 2001-07-05 Aventis Pharma Limited Azaindoles
GB9930698D0 (en) * 1999-12-24 2000-02-16 Rhone Poulenc Rorer Ltd Chemical compounds
WO2001057018A1 (en) * 2000-02-02 2001-08-09 Abbott Laboratories Azaazulene inhibitors of p38 map kinase and tnf-alpha
PE20020506A1 (en) * 2000-08-22 2002-07-09 Glaxo Group Ltd PIRAZOLE DERIVATIVES FUSED AS PROTEIN KINASE INHIBITORS
GB0112348D0 (en) 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
GB0115109D0 (en) * 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
EP1490364B1 (en) 2002-03-28 2007-09-26 Eisai R&D Management Co., Ltd. 7-azaindoles as inhibitors of c-jun n-terminal kinases for the treatment of neurodegenerative disorders
SG135051A1 (en) * 2002-06-20 2007-09-28 Aventis Pharma Ltd Azaindoles
EP1534282B1 (en) 2002-07-09 2006-12-27 Boehringer Ingelheim Pharma GmbH & Co.KG Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
GB0305142D0 (en) 2003-03-06 2003-04-09 Eisai London Res Lab Ltd Synthesis
WO2004078756A2 (en) * 2003-03-06 2004-09-16 Eisai Co., Ltd. Jnk inhibitors
EP1628975A2 (en) 2003-05-16 2006-03-01 Eisai Co., Ltd. Jnk inhibitors
ES2369835T3 (en) * 2003-11-19 2011-12-07 Array Biopharma, Inc. BICYCLIC MEK INHIBITORS AND SYNTHESIS METHODS OF THE SAME.
PL1696920T3 (en) 2003-12-19 2015-03-31 Plexxikon Inc Compounds and methods for development of ret modulators
GB0405055D0 (en) * 2004-03-05 2004-04-07 Eisai London Res Lab Ltd JNK inhibitors
US7498342B2 (en) 2004-06-17 2009-03-03 Plexxikon, Inc. Compounds modulating c-kit activity
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
PE20060777A1 (en) 2004-12-24 2006-10-06 Boehringer Ingelheim Int INDOLINONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES
EP1676574A3 (en) 2004-12-30 2006-07-26 Johnson & Johnson Vision Care, Inc. Methods for promoting survival of transplanted tissues and cells
ES2345629T3 (en) * 2005-05-16 2010-09-28 Irm Llc PIRROLOPIRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS.
GB0516156D0 (en) 2005-08-05 2005-09-14 Eisai London Res Lab Ltd JNK inhibitors
AU2006306991A1 (en) 2005-10-28 2007-05-03 Takeda Pharmaceutical Company Limited Heterocyclic amide compound and use thereof
CL2007002617A1 (en) 2006-09-11 2008-05-16 Sanofi Aventis COMPOUNDS DERIVED FROM PIRROLO [2,3-B] PIRAZIN-6-ILO; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE TO TREAT INFLAMMATION OF THE ARTICULATIONS, Rheumatoid Arthritis, TUMORS, LYMPHOMA OF THE CELLS OF THE MANTO.
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
NZ582772A (en) 2007-07-17 2012-06-29 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
AU2009257635A1 (en) * 2008-06-10 2009-12-17 Plexxikon, Inc. 5H-Pyrrolo [2,3-b] pyrazine derivatives for kinase modulation, and indications therefor
EP2955180B1 (en) 2009-04-03 2018-01-10 F. Hoffmann-La Roche AG Propane-i-sulfonic acid {3- [5- (4- chloro-phenyl) -1h-pyrrolo [2, 3-b} pyridine-3-carbonyl] -2, 4-difluoro-phenyl} -amide compositions and uses thereof
JP2013510166A (en) 2009-11-06 2013-03-21 プレキシコン インコーポレーテッド Compounds, methods and applications for kinase regulation
PL2672967T3 (en) 2011-02-07 2019-04-30 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
TWI558702B (en) 2011-02-21 2016-11-21 普雷辛肯公司 Solid forms of a pharmaceutically active substance
WO2013092467A1 (en) * 2011-12-20 2013-06-27 F. Hoffmann-La Roche Ag 7-azaindole inhibitors of crac
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
FR3001219A1 (en) * 2013-01-22 2014-07-25 Centre Nat Rech Scient KINASE INHIBITORS
DK3362450T3 (en) 2015-10-13 2020-09-14 Inst Nat Sante Rech Med N1- and N7-substituted sibiriline derivatives and their use as inhibitors of cellular necroptosis

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0871444A4 (en) * 1995-08-10 1999-01-13 Merck & Co Inc 2,5-substituted aryl pyrroles, compositions containing such compounds and methods of use

Also Published As

Publication number Publication date
AR012593A1 (en) 2000-11-08
ZA983452B (en) 1999-10-25
WO1998047899A1 (en) 1998-10-29

Similar Documents

Publication Publication Date Title
AU7132998A (en) Substituted pyrrolopyridines useful in the treatment of inflammatory diseases
IL132318A0 (en) Substituted imidazoles useful in the treatment of inflammatory diseases
IL142908A0 (en) Compounds useful in the treatment of inflammatory diseases
IL133766A0 (en) 2-substituted imidazoles useful in the treatment of inflammatory diseases
AU3441197A (en) 3-ureido-pyridofurans and -pyridothiophenes for the treatment of inflammatory processes
PL344451A1 (en) Use of cyclosporins in the treatment of inflammatory autoimmune diseases
ZA984174B (en) Novel triptolide derivatives useful in the treatment of autoimmune diseases
AU9395998A (en) Compositions and methods for the treatment of immune related diseases
AU2418499A (en) Org-5222 in the treatment of depression
AU5056099A (en) Compounds for use in the treatment of inflammation
AU2001260834A1 (en) The treatment of herpes
IL133089A0 (en) Novel triptolide derivatives useful in the treatment of autoimmune diseases
AU6281298A (en) Use of lofexidine in the treatment of behavioral disorders
AU2529799A (en) Benzofuran-4-carboxamides and their therapeutic use
AU2705495A (en) Use of rooperol and hypoxoside and their derivatives in the treatment of inflammatory
AU8049098A (en) Composition and methods for the treatment of inflammatory diseases
AU8760298A (en) Coup-tfi directed therapies in the treatment of disease
AU9082698A (en) Treatment of inflammatory conditions
AU3838695A (en) Use of the bio-spectrum in animal embryo-engineering
AU2002300624A1 (en) Substituted imidazoles useful in the treatment of inflammatory diseases
AU6408598A (en) Unsatured fatty acid anhydrides for use in the therapy
AU1801297A (en) Spiro-ketal derivatives and their use as therapeutic agents
AU2002306210A1 (en) 2-substituted imidazoles useful in the treatment of inflammatory diseases
AU7639998A (en) Pyrrolo{2,1,5-cd}indolizine derivatives useful in the prevention or treatment ofestrogen related diseases or syndromes
AU5582899A (en) Formamides as therapeutic agents

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase